NEPH Insider Trading (Nephros)
Insider Ownership Percentage: 8.60%
Insider Buying (Last 12 Months): $65,295.00
Insider Selling (Last 12 Months): $0.00
Nephros Share Price & Price History
Current Price: $1.79
Price Change: ▼ Price Decrease of -0.07 (-3.76%)
As of 05/20/2022 01:00 AM ET
How You Should Be Choosing Your Stocks
From Vantage Point | Ad
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Nephros Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/20/2021 | Wesley S. Lobo | CMO | Buy | 1,000 | $7.92 | $7,920.00 | |  |
| 8/18/2021 | Tom Gwydir | Director | Buy | 5,000 | $7.64 | $38,200.00 | 11,031 | |
| 8/17/2021 | Andrew Astor | CEO | Buy | 2,500 | $7.67 | $19,175.00 | 75,458 | |
| 11/19/2020 | Andrew Astor | CEO | Buy | 1,000 | $5.87 | $5,870.00 | 72,958 | |
| 8/19/2020 | Andrew Astor | CFO | Buy | 950 | $7.40 | $7,030.00 | 71,958 | |
| 5/28/2020 | Andrew Astor | CFO | Buy | 1,000 | $7.80 | $7,800.00 | | |
| 3/5/2020 | Daron Evans | CEO | Buy | 2,500 | $8.25 | $20,625.00 | | |
| 11/25/2019 | Oliver J Spandow | Director | Buy | 1,000 | $8.42 | $8,420.00 | | |
| 11/18/2019 | Daron Evans | CEO | Buy | 1,000 | $8.30 | $8,300.00 | | |
| 8/22/2019 | Andrew Astor | CFO | Buy | 1,500 | $6.97 | $10,455.00 | | |
| 8/22/2019 | Daron Evans | Insider | Buy | 2,000 | $6.92 | $13,840.00 | | |
| 6/14/2019 | Andrew Astor | CFO | Buy | 35,000 | $0.64 | $22,400.00 | | |
| 6/14/2019 | Daron Evans | Insider | Buy | 43,172 | $0.60 | $25,903.20 | | |
Warning: The Last Value Play Gone After August?
From Oxford Club | Ad
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.
But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Nephros Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2022 | Wexford Capital LP | 3,663,969 | $533.73M | 26.0% | +0.4% | 35.507% |  |
| 5/13/2022 | Renaissance Technologies LLC | 20,317 | $89K | 0.0% | N/A | 0.197% | |
| 5/11/2022 | Bard Associates Inc. | 246,408 | $1.08M | 0.4% | +6.0% | 2.388% | |
| 5/10/2022 | Elkhorn Partners Limited Partnership | 23,712 | $0.10M | 0.1% | +56.0% | 0.230% | |
| 5/4/2022 | Advisor Group Holdings Inc. | 8,674 | $38K | 0.0% | +89.6% | 0.084% | |
| 5/2/2022 | Cowen Prime Advisors LLC | 80,400 | $0.35M | 0.1% | -87.3% | 0.780% | |
| 2/19/2022 | Wexford Capital LP | 3,650,529 | $646.53M | 27.0% | N/A | 35.674% | |
| 2/14/2022 | Elkhorn Partners Limited Partnership | 15,200 | $90K | 0.1% | +78.8% | 0.149% | |
| 2/8/2022 | Cowen Prime Advisors LLC | 633,050 | $3.74M | 1.3% | -4.1% | 6.186% | |
| 2/8/2022 | Samjo Capital LLC | 425,000 | $2.51M | 1.7% | -22.7% | 4.153% | |
| 11/16/2021 | Millennium Management LLC | 13,424 | $0.12M | 0.0% | -10.6% | 0.131% | |
| 11/15/2021 | Morgan Stanley | 13,837 | $0.12M | 0.0% | +186.3% | 0.135% | |
| 11/9/2021 | BlackRock Inc. | 18,079 | $0.16M | 0.0% | -23.0% | 0.177% | |
| 11/2/2021 | Cowen Prime Advisors LLC | 660,150 | $5.79M | 2.2% | +5.4% | 6.461% | |
| 8/17/2021 | Wexford Capital LP | 3,631,197 | $36.85M | 5.6% | +1.9% | 35.541% | |
| 8/17/2021 | Millennium Management LLC | 15,023 | $0.16M | 0.0% | -20.6% | 0.147% | |
| 8/13/2021 | Vanguard Group Inc. | 99,936 | $1.01M | 0.0% | +3.9% | 0.978% | |
| 8/12/2021 | Bard Associates Inc. | 231,508 | $2.35M | 0.8% | +5.5% | 2.266% | |
| 8/4/2021 | Cowen Prime Advisors LLC | 626,450 | $6.36M | 2.3% | N/A | 6.290% | |
| 8/2/2021 | Advisor Group Holdings Inc. | 4,574 | $46K | 0.0% | +91,380.0% | 0.046% | |
| 5/21/2021 | Citadel Advisors LLC | 18,421 | $0.12M | 0.0% | N/A | 0.185% | |
| 5/18/2021 | Millennium Management LLC | 18,909 | $0.13M | 0.0% | -10.4% | 0.190% | |
| 5/18/2021 | Citadel Advisors LLC | 18,421 | $0.12M | 0.0% | N/A | 0.185% | |
| 5/13/2021 | Wexford Capital LP | 3,564,530 | $23.70M | 3.5% | +0.1% | 35.781% | |
| 5/7/2021 | BlackRock Inc. | 23,559 | $0.16M | 0.0% | +20.9% | 0.237% | |
| 4/27/2021 | Cowen Prime Services LLC | 622,750 | $4.14M | 1.6% | +8.3% | 6.258% | |
| 2/12/2021 | Elkhorn Partners Limited Partnership | 14,290 | $0.12M | 0.1% | -9.0% | 0.145% | |
| 2/11/2021 | Samjo Capital LLC | 550,000 | $4.72M | 4.0% | N/A | 5.575% | |
| 2/10/2021 | HighTower Advisors LLC | 55,710 | $0.48M | 0.0% | +28.9% | 0.565% | |
| 1/27/2021 | Cowen Prime Services LLC | 575,077 | $4.93M | 2.2% | +86.1% | 5.829% | |
| 11/6/2020 | BlackRock Inc. | 18,333 | $0.13M | 0.0% | -28.1% | 0.203% | |
| 10/29/2020 | Cowen Prime Services LLC | 309,009 | $2.23M | 1.1% | +22.6% | 3.418% | |
| 8/12/2020 | Blair William & Co. IL | 36,249 | $0.30M | 0.0% | +5.8% | 0.401% | |
| 7/29/2020 | Cowen Prime Services LLC | 251,994 | $2.11M | 1.0% | +62.8% | 2.798% | |
| 5/18/2020 | Wexford Capital LP | 3,395,579 | $21.39M | 7.9% | N/A | 37.699% | |
| 5/4/2020 | Essex Investment Management Co. LLC | 39,863 | $0.25M | 0.1% | N/A | 0.443% | |
| 5/1/2020 | BlackRock Inc. | 8,659 | $54K | 0.0% | +238.0% | 0.096% | |
| 4/28/2020 | Cowen Prime Services LLC | 154,800 | $0.98M | 0.6% | N/A | 1.719% | |
| 4/22/2020 | Ingalls & Snyder LLC | 133,140 | $0.84M | 0.1% | -1.0% | 1.478% | |
| 2/13/2020 | Parkman Healthcare Partners LLC | 199,724 | $1.99M | 0.6% | N/A | 2.478% | |
| 2/10/2020 | National Asset Management Inc. | 14,254 | $0.14M | 0.0% | -45.5% | 0.177% | |
| 1/15/2020 | Ingalls & Snyder LLC | 134,539 | $1.34M | 0.1% | +104.5% | 1.690% | |
| 11/27/2019 | Millennium Management LLC | 38,521 | $0.31M | 0.0% | N/A | 0.484% | |
Data available starting January 2016
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Read More on Nephros
Volume
22,009 shs
Average Volume
113,106 shs
Market Capitalization
$18.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
Who are the company insiders with the largest holdings of Nephros?
Who are the major institutional investors of Nephros?
Nephros' top institutional investors include:
- Wexford Capital LP — 35.51%
- Bard Associates Inc. — 2.39%
- Cowen Prime Advisors LLC — 0.78%
- Elkhorn Partners Limited Partnership — 0.23%
- Renaissance Technologies LLC — 0.20%
- Advisor Group Holdings Inc. — 0.08%
Learn More about top institutional investors of Nephros stock.
Which major investors are selling Nephros stock?
In the last quarter, NEPH stock was sold by these institutional investors:
- Cowen Prime Advisors LLC
Which major investors are buying Nephros stock?
Within the last quarter, NEPH stock was purchased by institutional investors including:
- Renaissance Technologies LLC
- Bard Associates Inc.
- Wexford Capital LP
- Elkhorn Partners Limited Partnership
- Advisor Group Holdings Inc.
During the last year, these company insiders have bought Nephros stock:
- Andrew Astor (CEO)
- Andrew Astor (CFO)
- Tom Gwydir (Director)
- Wesley S Lobo (CMO)
Learn More investors buying Nephros stock.
